The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology
Open accessAbstract
Neurofibrillary tangles (NFTs) are composed of abnormal aggregates of the cytoskeletal protein tau. Together with amyloid β (Aβ) plaques and neuronal and synaptic loss, NFTs constitute the primary pathological hallmarks of Alzheimer disease (AD). Recent evidence also suggests that caspases are activated early in the progression of AD and may play a role in neuronal loss and NFT pathology. Here we demonstrate that tau is cleaved at D421 (ΔTau) by executioner caspases. Following caspase-cleavage, ΔTau facilitates nucleation-dependent filament formation and readily adopts a conformational change recognized by the early pathological tau marker MC1. ΔTau can be phosphorylated by glycogen synthase kinase-3β and subsequently recognized by the NFT antibody PHF-1. In transgenic mice and AD brains, ΔTau associates with both early and late markers of NFTs and is correlated with cognitive decline. Additionally, ΔTau colocalizes with Aβ1–42 and is induced by Aβ1–42 in vitro. Collectively, our data imply that Aβ accumulation triggers caspase activation, leading to caspase-cleavage of tau, and that this is an early event that may precede hyperphosphorylation in the evolution of AD tangle pathology. These results suggest that therapeutics aimed at inhibiting tau caspase-cleavage may prove beneficial not only in preventing NFT formation, but also in slowing cognitive decline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is consistent with the observation that C-terminal truncated forms of Tau show increased polymerization capacity in vitro and are associated with NFTs formation in the brain of AD patients (Gamblin et al., 2003; Rissman et al., 2004).”
From Emerging Alternative Proteinases in APP Metabolism and Alzheimer’s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP (2019) · cites this paper as Rissman et al., 2004
In the citing paper
“Δtau levels were below the detectable level in our 7-month-old, untreated 3xTg-AD mice”
From The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease (2011) · cites this paper as Rissman et al., 2004
In the citing paper
“Recent evidence suggests that executioner caspases 3 and 7 may contribute to tau, the protein responsible for forming NFTs, pathology by cleaving tau after Asp421 to yield a cytotoxic Δtau fragment (Rissman et al., 2004; Rohn et al., 2008; de Calignon et al., 2010).”
From The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease (2011) · cites this paper as Rissman et al., 2004
In the citing paper
“only caspase-2, 3 and 6 cleaved tau products have been linked to AD [190–193].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [192]
In the citing paper
“Although tau can be cleaved by caspase-1, 2, 3, 6 and 7 in vitro”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [192]
In the citing paper
“Tau-421 colocalizes with NFTs in human AD brain, and correlates with NFT formation and cognitive impairment in aged mice [191, 192, 194].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [192]
In the citing paper
“Elevated levels of caspase-3 and tau-421 have been observed in AD, as well as PSP [130, 191, 192].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [192]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics
Kerr, J. F. R., Wyllie, A. H., & Currie, A. R. (1972) · British Journal of Cancer · doi:10.1038/bjc.1972.33 · Cited by 15,673
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Self-citationLee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Buée, L., Bussière, T., Buée‐Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,142
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.
Grundke, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38495-8 · Cited by 1,780
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526
Flagged first, then by citations
Research works printed but not linked: 1
- Yang, 1998, Am. J. Pathol., 152, 379
Cited by
Sorted by citations
Items 101–200 of 544
Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy
Barini, E., Antico, O., Zhao, Y., Asta, F., Tucci, V., Catelani, T., Marotta, R., Xu, H., & Gasparini, L. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0082-7 · Cited by 126
The putative neurodegenerative links between depression and Alzheimer's disease
Wuwongse, S., Chang, R. C., & Law, A. C. K. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.005 · Cited by 126
Trends in the Molecular Pathogenesis and Clinical Therapeutics of Common Neurodegenerative Disorders
Choonara, Y. E., Pillay, V., du Toit, L. C., Modi, G., Naidoo, D., Ndesendo, V. M. K., & Sibambo, S. R. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10062510 · Cited by 126
Mouser, P. E., Head, E., Ha, K.-H., & Rohn, T. T. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050798 · Cited by 121
Self-citationAnalysis of Tau Phosphorylation and Truncation in a Mouse Model of Human Tauopathy
Delobel, P., Lavenir, I., Fraser, G. M., Ingram, E., Holzer, M., Ghetti, B. F., Spillantini, M. G., Crowther, R. A., & Goedert, M. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070627 · Cited by 124
Cieri, D., Vicario, M., Vallese, F., D’Orsi, B., Berto, P., Grinzato, A., Catoni, C., Stefani, D. D., Rizzuto, R., Brini, M., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.07.011 · Cited by 124
Brain Insulin Dysregulation: Implication for Neurological and Neuropsychiatric Disorders
Ghasemi, R., Dargahi, L., Haeri, A., Moosavi, M., Mohamed, Z., & Ahmadiani, A. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8404-z · Cited by 123
Madeira, A., Pommet, J., Prochiantz, A., & Allinquant, B. (2005) · The FASEB Journal · doi:10.1096/fj.05-3839fje · Cited by 102
Young, M. L., & Franklin, J. L. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.103409 · Cited by 120
NMR Investigation of the Interaction between the Neuronal Protein Tau and the Microtubules
Sillen, A., Barbier, P., Landrieu, I., Lefebvre, S., Wieruszeski, J., Leroy, A., Peyrot, V., & Lippens, G. M. (2007) · Biochemistry · doi:10.1021/bi061920i · Cited by 121
Disease modifying therapy for AD?1
Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117
Ding, H., Matthews, T. A., & Johnson, G. V. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511697200 · Cited by 112
Di, J., Cohen, L. S., Corbo, C. P., Phillips, G. R., Idrissi, A. E., & Alonso, A. D. C. (2016) · Scientific Reports · doi:10.1038/srep20833 · Cited by 120
The role of caspases in Alzheimer’s disease; potential novel therapeutic opportunities
Rohn, T. T. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0463-2 · Cited by 112
Self-citationTherapeutic strategies for the treatment of tauopathies: Hopes and challenges
Khanna, M. R., Kovalevich, J., Lee, V. M. ‐., Trojanowski, J. Q., & Brunden, K. R. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.006 · Cited by 116
Hyperphosphorylation-Induced Tau Oligomers
Iqbal, K., Gong, C., & Liu, F. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00112 · Cited by 120
Precision pharmacology for Alzheimer’s disease
Hampel, H. J., Vergallo, A., Aguilar, L. F., Benda, N., Broich, K., Cuello, A. C., Cummings, J. L., Dubois, B., Federoff, H. J., Fiandaca, M. S., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.014 · Cited by 114
Wiciński, M., Wódkiewicz, E., Górski, K. M., Walczak, M., & Malinowski, B. (2020) · Pharmaceuticals · doi:10.3390/ph13110379 · Cited by 111
Luna‐Muñoz, J., García‐Sierra, F., Falcón, V., Menéndez, I., Chávez-Macías, L., & Mena, R. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8104 · Cited by 113
Evaluating triggers and enhancers of tau fibrillization
Kuret, J., Congdon, E. E., Li, G., Yin, H., Yu, X., & Zhong, Q. (2005) · Microscopy Research and Technique · doi:10.1002/jemt.20187 · Cited by 119
Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer's disease
Ramalho, R. M., Viana, R. J. S., Low, W. C., Steer, C. J., & Rodrigues, C. M. P. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.001 · Cited by 107
Ljungberg, M. C., Ali, Y. O., Zhu, J., Wu, C.-S., Oka, K., Zhai, R. G., & Lu, H.-C. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr492 · Cited by 107
Kanaan, N. M., Cox, K. K., Alvarez, V. E., Stein, T. D., Poncil, S., & McKee, A. C. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlv001 · Cited by 110
Truncation of Tau selectively facilitates its pathological activities
Gu, J., Xu, W., Jin, N., Li, L., Zhou, Y., Chu, D., Gong, C., Iqbal, K., & Liu, F. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012587 · Cited by 108
Apolipoprotein E: Implications for AD neurobiology, epidemiology and risk assessment
Schipper, H. M. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.021 · Cited by 113
Fuentealba, R. A., Liu, Q., Kanekiyo, T., Zhang, J., & Bu, G. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.021030 · Cited by 97
Salminen, A., Haapasalo, A., Kauppinen, A., Kaarniranta, K., Soininen, H. S., & Hiltunen, M. O. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.001 · Cited by 107
Figueiredo‐Pereira, M. E., Rockwell, P., Schmidt‐Glenewinkel, T., & Serrano, P. A. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00104 · Cited by 105
Cleavage of Tau by calpain in Alzheimer's disease: the quest for the toxic 17 kD fragment
Garg, S., Timm, T., Mandelkow, E.-M., Mandelkow, E., & Wang, Y. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.09.008 · Cited by 103
Zhao, Y., Tseng, I.-C., Heyser, C. J., Rockenstein, E., Mante, M., Adame, A., Zheng, Q., Huang, T., Wang, X., Arslan, P. E., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.08.020 · Cited by 98
Mechanisms of neuronal death in disease: defining the models and the players
Ribé, E. M., Serrano‐Saiz, E., Akpan, N., & Troy, C. M. (2008) · Biochemical Journal · doi:10.1042/bj20081118 · Cited by 107
The Proteasome and Oxidative Stress in Alzheimer's Disease
Bonet-Costa, V., Pomatto, L. C.-D., & Davies, K. J. A. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6802 · Cited by 99
Truncation of Tau Protein and its Pathological Significance in Alzheimer's Disease
García‐Sierra, F., Mondragón‐Rodríguez, S., & Basurto‐Islas, G. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14407 · Cited by 109
Frozza, R. L., Horn, A. P., Hoppe, J. B., Simão, F., Gerhardt, D., Comiran, R. A., & Salbego, C. G. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9776-8 · Cited by 108
Aggregation of Disordered Proteins Associated with Neurodegeneration
Tsoi, P. S., Quan, M. D., Ferreon, J. C., & Ferreon, A. C. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043380 · Cited by 103
Human High Temperature Requirement Serine Protease A1 (HTRA1) Degrades Tau Protein Aggregates
Tennstaedt, A., Poepsel, S., Truebestein, L., Hauske, P., Brockmann, A., Schmidt, N., Irle, I., Saccà, B., Niemeyer, C. M., Brandt, R., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.316232 · Cited by 104
Direct cellular delivery of human proteasomes to delay tau aggregation
Han, D. H., Na, H.-K., Choi, W. H., Lee, J. H., Kim, Y. K., Won, C., Lee, S.-H., Kim, K. P., Kuret, J., Min, D.-H., et al. (2014) · Nature Communications · doi:10.1038/ncomms6633 · Cited by 88
The Role of Tau in Neurodegenerative Diseases and Its Potential as a Therapeutic Target
Wolfe, M. S. (2012) · Scientifica · doi:10.6064/2012/796024 · Cited by 105
The Effects of NOS2 Gene Deletion on Mice Expressing Mutated Human AβPP
Colton, C. A., Wilcock, D. M., Wink, D. A., Davis, J., Nostrand, W. E. V., & Vitek, M. P. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15405 · Cited by 92
Self-citationTremblay, C., St‐Amour, I., Schneider, J. A., Bennett, D. A., & Calon, F. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31822c62cf · Cited by 98
Duarte, A. I., Candeias, E., Alves, I. N., Mena, D., da Silva, D. F., Machado, N. J., Campos, E. J., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051746 · Cited by 94
Removing Protein Aggregates: The Role of Proteolysis in Neurodegeneration
Nijholt, D. A. T., Kimpe, L. D., Elfrink, H. L., Hoozemans, J. J. M., & Scheper, W. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795843236 · Cited by 96
Wang, L., Bharti, Kumar, R., Pavlov, P. F., & Winblad, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112915 · Cited by 92
Serological muscle loss biomarkers: an overview of current concepts and future possibilities
Nedergaard, A., Karsdal, M., Sun, S., & Henriksen, K. (2012) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-012-0086-2 · Cited by 76
Glushakova, O. Y., Glushakov, A. O., Borlongan, C. V., Valadka, A. B., Hayes, R. L., & Glushakov, A. V. (2017) · Journal of Neurotrauma · doi:10.1089/neu.2017.4999 · Cited by 92
Park, S.-Y., Tournell, C. E., Sinjoanu, R. C., & Ferreira, A. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.09.012 · Cited by 91
Wiciński, M., Socha, M. W., Malinowski, B., Wódkiewicz, E., Walczak, M., Górski, K. M., Słupski, M., & Pawlak-Osińska, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051050 · Cited by 94
Frontal Cortex Neuropathology in Dementia Pugilistica
Saing, T., Dick, M. B., Nelson, P. T., Kim, R. C., Cribbs, D. H., & Head, E. (2011) · Journal of Neurotrauma · doi:10.1089/neu.2011.1957 · Cited by 92
Chu, J., Lauretti, E., & Praticò, D. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.214 · Cited by 90
The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics
Pritchard, S. M., Dolan, P. J., Vitkus, A., & Johnson, G. V. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01273.x · Cited by 89
García-González, L., Pilat, D., Baranger, K., & Rivera, S. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00244 · Cited by 88
Brain injury-induced dysfunction of the blood brain barrier as a risk for dementia
Abrahamson, E. E., & Ikonomović, M. D. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113257 · Cited by 91
Tau Aggregates: Toxic, Inert, or Protective Species?
Bretteville, A., & Planel, E. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14411 · Cited by 87
Zinc-mediated Allosteric Inhibition of Caspase-6
Velázquez-Delgado, E. M., & Hardy, J. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.397752 · Cited by 84
Holubová, M., Hrubá, L., Popelová, A., Bencze, M., Pražienková, V., Gengler, S., Kratochvílová, H., Haluzı́k, M., Železná, B., Kuneš, J., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.11.002 · Cited by 82
The Hsp90 Kinase Co-chaperone Cdc37 Regulates Tau Stability and Phosphorylation Dynamics
Jinwal, U. K., Trotter, J. H., Abisambra, J. F., Koren, J., Lawson, L. Y., Vestal, G. D., O’Leary, J. C., Johnson, A. G., Jin, Y., Jones, J. R., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.182493 · Cited by 84
Vandebroek, T., Vanhelmont, T., Terwel, D., Borghgraef, P., Lemaire, K., Snauwaert, J., Wera, S., LEUVEN, F. V., & Winderickx, J. (2005) · Biochemistry · doi:10.1021/bi0506775 · Cited by 82
Abnormal Mitochondrial Dynamics—A Novel Therapeutic Target for Alzheimer's Disease?
Su, B., Wang, X., Bonda, D., Perry, G. L., Smith, M. A., & Zhu, X. (2010) · Molecular Neurobiology · doi:10.1007/s12035-009-8095-7 · Cited by 85
Caspase-Cleaved Tau Impairs Mitochondrial Dynamics in Alzheimer’s Disease
Pérez, M. J., Vergara-Pulgar, K., Jara, C., Cabezas-Opazo, F., & Quintanilla, R. A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0385-x · Cited by 81
Meier, S. E., Bell, M. C., Lyons, D. N., Ingram, A., Chen, J., Gensel, J. C., Zhu, H., Nelson, P. T., & Abisambra, J. F. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150298 · Cited by 84
Accelerated Human Mutant Tau Aggregation by Knocking Out Murine Tau in a Transgenic Mouse Model
Ando, K., Leroy, K., Héraud, C., Yilmaz, Z., Authelet, M., Suain, V., Decker, R. D., & Brion, J. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.10.034 · Cited by 80
Héraud, C., Goufak, D., Ando, K., Leroy, K., Suain, V., Yilmaz, Z., De Decker, R., Authelet, M., Laporte, V., Octave, J.-N., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.010 · Cited by 80
Phosphorylation of Human Tau Protein by Microtubule Affinity-Regulating Kinase 2
Schwalbe, M., Biernat, J., Bibow, S., Ozenne, V., Jensen, M. R., Kadavath, H., Blackledge, M., Mandelkow, E., & Zweckstetter, M. (2013) · Biochemistry · doi:10.1021/bi401266n · Cited by 78
δ-secretase in neurodegenerative diseases: mechanisms, regulators and therapeutic opportunities
Zhang, Z., Tian, Y., & Ye, K. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-019-0179-3 · Cited by 81
Dawson, H. N., Cantillana, V., Chen, L., & Vitek, M. P. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.5492-06.2007 · Cited by 80
Self-citationSpecificity for latent C termini links the E3 ubiquitin ligase CHIP to caspases
Ravalin, M., Theofilas, P., Basu, K., Opoku-Nsiah, K., Assimon, V. A., Medina-Cleghorn, D., Chen, Y., Bohn, M., Arkin, M. R., Grinberg, L. T., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0322-6 · Cited by 80
Caspase-cleaved TAR DNA-binding protein-43 is a major pathological finding in Alzheimer's disease
Rohn, T. T. (2008) · Brain Research · doi:10.1016/j.brainres.2008.06.094 · Cited by 77
Self-citationWu, X., Piña-Crespo, J., Zhang, Y., Chen, X., & Xu, H. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.220313 · Cited by 82
Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease
Iqbal, K., Gong, C., & Liu, F. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.870156 · Cited by 76
Serum Tau Fragments Predict Return to Play in Concussed Professional Ice Hockey Players
Shahim, P., Linemann, T., Inekci, D., Karsdal, M. A., Blennow, K., Tegner, Y., Zetterberg, H., & Henriksen, K. (2015) · Journal of Neurotrauma · doi:10.1089/neu.2014.3741 · Cited by 76
Prà, I. D., Chiarini, A., Gui, L., Chakravarthy, B., Pacchiana, R., Gardenal, E., Whitfield, J. F., & Armato, U. (2014) · The Neuroscientist · doi:10.1177/1073858414529828 · Cited by 79
Screening for Inhibitors of Tau Polymerization
Pickhardt, M., von Bergen�, M., Gažová, Z., Hascher, A., Biernat, J., Mandelkow, E., & Mandelkow�, E. (2005) · Current Alzheimer Research · doi:10.2174/1567205053585891 · Cited by 74
Arena, J. D., Smith, D. H., Lee, E. B., Gibbons, G. S., Irwin, D. J., Robinson, J. L., Lee, V. M. ‐., Trojanowski, J. Q., Stewart, W. B., Jr., & Johnson, V. E. (2020) · Brain · doi:10.1093/brain/awaa071 · Cited by 77
Gerson, J. E., Castillo‐Carranza, D. L., & Kayed, R. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500143n · Cited by 75
Tau Phosphorylation and Cleavage in Ethanol-Induced Neurodegeneration in the Developing Mouse Brain
Saito, M., Chakraborty, G., Mao, R.-F., Paik, S.-M., Vadász, C., & Saito, M. (2010) · Neurochemical Research · doi:10.1007/s11064-009-0116-4 · Cited by 72
Caspases as therapeutic targets
Howley, B. A., & Fearnhead, H. O. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00292.x · Cited by 73
Higuchi, M., Iwata, N., & Saido, T. C. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.02.013 · Cited by 73
Kim, Y., Choi, H., Lee, W., Park, H., Kam, T.-I., Hong, S.-H., Nah, J., Jung, S., Shin, B., Lee, H., et al. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.12.006 · Cited by 71
Kim, B., Backus, C., Oh, S., & Feldman, E. L. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121669 · Cited by 74
Protein phosphatase 2A and tau: an orchestrated ‘Pas de Deux’
Taleski, G., & Sontag, E. (2017) · FEBS Letters · doi:10.1002/1873-3468.12907 · Cited by 71
The necroptosis cell death pathway drives neurodegeneration in Alzheimer’s disease
Balusu, S., & Strooper, B. D. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02747-5 · Cited by 76
Extensive p‐Tau Pathology and SDS‐Stable p‐Tau Oligomers in Alzheimer's Cortical Synapses
Henkins, K. M., Sokolow, S., Miller, C. A., Vinters, H. V., Poon, W. W., Cornwell, L. B., Saing, T., & Gylys, K. H. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00598.x · Cited by 69
Self-citationMatsumoto, S.-E., Motoi, Y., Ishiguro, K., Tabira, T., Kametani, F., Hasegawa, M., & Hattori, N. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv351 · Cited by 66
Kulbe, J. R., & Hall, E. D. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.08.003 · Cited by 70
Tau phosphorylation and proteolysis: Insights and perspectives
Johnson, G. V. W. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s326 · Cited by 69
C‐terminal truncation modulates both nucleation and extension phases of τ fibrillization
Yin, H., & Kuret, J. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.11.077 · Cited by 72
Caspases in Alzheimer’s Disease: Mechanism of Activation, Role, and Potential Treatment
Wójcik, P., Jastrzębski, M. K., Zięba, A., Matosiuk, D., & Kaczor, A. A. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03847-1 · Cited by 78
Impact of Tau on Neurovascular Pathology in Alzheimer's Disease
Canepa, E., & Fossati, S. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2020.573324 · Cited by 67
Phosphorylation and cleavage of tau in non-AD tauopathies
Guillozet-Bongaarts, A. L., Glajch, K. E., Libson, E. G., Cahill, M. E., Bigio, E. H., Berry, R. W., & Binder, L. I. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0209-6 · Cited by 65
Koch, G., Di Lorenzo, F., Loizzo, S., Motta, C., Travaglione, S., Baiula, M., Rimondini, R., Ponzo, V., Bonnì, S., Toniolo, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14204-3 · Cited by 64
Corsetti, V., Amadoro, G., Gentile, A., Capsoni, S., Ciotti, M. T., Cencioni, M. T., Atlante, A., Canu, N., Rohn, T. T., Cattaneo, A., et al. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.03.011 · Cited by 68
Self-citationThe Role of Eicosanoids in Alzheimer’s Disease
Biringer, R. G. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16142560 · Cited by 65
Caspase-Mediated Degeneration in Alzheimer's Disease
Cribbs, D. H., Poon, W. W., Rissman, R. A., & Blurton-Jones, M. M. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63302-0 · Cited by 64
Self-citationFormation of Phospho-SAPK/JNK Granules in the Hippocampus Is an Early Event in Alzheimer Disease
Lagalwar, S., Guillozet-Bongaarts, A. L., Berry, R. W., & Binder, L. I. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000229236.98124.d8 · Cited by 62
Caspases as therapeutic targets in Alzheimer's disease: is it time to "cut" to the chase?
Rohn, T. T., & Head, E. (2009) · PubMed Central · Cited by 63
Self-citationSahara, N., Murayama, M., Lee, B., Park, J., Lagalwar, S., Binder, L. I., & Takashima, A. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06258.x · Cited by 63
Chun, W., Waldo, G. S., & Johnson, G. V. W. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04941.x · Cited by 63
Glushakova, O., Glushakov, A. V., Glushakov, A. O., Wijesinghe, D. S., Valadka, A. B., & Hayes, R. (2017) · Brain Circulation · doi:10.4103/bc.bc_27_16 · Cited by 65
Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target
Oakley, S. S., Maina, M. B., Marshall, K. E., Al‐Hilaly, Y. K., Harrington, C., Wischik, C. M., & Serpell, L. C. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.590754 · Cited by 59
Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation
Reilly, P., Winston, C. N., Baron, K. R., Trejo, M., Rockenstein, E. M., Akers, J. C., Kfoury, N., Diamond, M. I., Masliah, E., Rissman, R. A., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.06.005 · Cited by 61
Self-citation
Metadata
- Authors
- Rissman, R. A., Poon, W. W., Blurton-Jones, M., Oddo, S., Torp, R., Vitek, M. P., LaFerla, F. M., Rohn, T. T., & Cotman, C. W.
- Affiliations
- University of California, Irvine (US)
- Duke Medical Center (US)
- Boise State University (US)
- Corresponding author
- Cotman, Carl W.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2004-07-01
- Volume
- 114
- Issue
- 1
- Pages
- 121-130
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC437967
- OpenAlex
- W1989856924
- Cited by
- 543
- References
- 82
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 20 · 2023: 20 · 2022: 20 · 2021: 23 · 2020: 32 · 2019: 28 · 2018: 33 · 2017: 24 · 2016: 30 · 2015: 26 · 2014: 19 · 2013: 27 · 2012: 30
- FWCI
- 13.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ScholarWorks (Boise State University) (submittedVersion)
- Funders
- National Institutes of Health (1r03ag019386-01, AG016573, AG000096, AG000538)
- National Institute on Aging (P01AG000538, AG19386, AG19780, AG-000538, AG17968, AG000096, R01AG017968, P50AG016573, F32AG023433, AG023433, R01AG019780, T32AG000096)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- tau cleavage, caspase activation, neurofibrillary tangles, Alzheimer's disease, amyloid-beta, glycogen synthase kinase-3β, tau phosphorylation, PHF1, cognitive decline, mild cognitive impairment, traumatic brain injury, triple transgenic mouse model
- MeSH terms
- Alzheimer Disease, Animals, Humans, Membrane Proteins, Mice, Transgenic, Phosphorylation, Reference Values, Neurofibrillary Tangles, tau Proteins, Pyramidal Cells, Mice, Knockout, Caspases, Mice, Presenilin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
